Cancer Institute And Hospital, Chinese Academy Of Medical Sciences
Clinical trials sponsored by Cancer Institute And Hospital, Chinese Academy Of Medical Sciences, explained in plain language.
-
New drug combo aims to shrink liver tumors for surgery
Disease control Recruiting nowThis study is testing whether a new drug called ivonescimab, when combined with standard chemotherapy, can shrink colorectal cancer tumors that have spread only to the liver and are currently inoperable. The goal is to see if this treatment makes the tumors small enough for surge…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Apr 01, 2026 21:56 UTC
-
New drug approach tested before cancer surgery
Disease control Recruiting nowThis study observes how well the drug tislelizumab works when given before surgery to patients with a specific type of stage II or III colorectal cancer. About 30 patients will receive three cycles of the drug, then have surgery, and be followed for five years. The goal is to see…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New scan aims to sharpen cancer surgery, spare healthy tissue
Disease control Recruiting nowThis study is testing whether a new type of PET-CT scan can help surgeons better see and remove all medullary thyroid cancer during an operation. 150 newly diagnosed patients will be randomly assigned to have surgery guided by this new scan or by the surgeon's standard approach. …
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Major trial seeks best Pre-Surgery combo to fight deadly esophageal cancer
Disease control Recruiting nowThis large study aims to find the best pre-surgery treatment combination for patients with esophageal cancer, which has a low survival rate. Researchers will compare different approaches, including chemotherapy, radiation, immunotherapy, and targeted drugs, given before surgery. …
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New combo attack on lung Cancer's spread to the brain
Disease control Recruiting nowThis study is testing whether adding a drug called anlotinib to standard whole-brain radiation therapy works better than radiation alone for people with small cell lung cancer that has spread to the brain. The goal is to better control the cancer in the brain and help patients li…
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug combo trial offers hope for rare immune disorder
Disease control Recruiting nowThis study is testing whether a combination of two existing drugs, lenalidomide and dexamethasone, can help control Rosai-Dorfman disease, a rare disorder where the immune system causes tissue damage. The trial will enroll 40 adults with the condition to see how well the treatmen…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 31, 2026 12:18 UTC
-
Scientists test supercharged immune cells against tough cancers
Disease control Recruiting nowThis study is testing a new type of cell therapy for people with advanced solid tumors that have not responded to standard treatments. Doctors take a patient's own immune cells from a tumor sample, modify them in the lab to potentially work better, and then infuse them back into …
Phase: EARLY_PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Scientists test 'In-Body' cancer cell therapy in groundbreaking trial
Disease control Recruiting nowThis early-stage study is testing the safety of a new type of cancer treatment called in vivo CAR-T therapy (V001 Injection). It aims to see if the treatment is safe and tolerable for up to 50 adults with advanced cancers that have not responded to other treatments. The study wil…
Phase: EARLY_PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for advanced colon cancer: boosting chemo with immune drugs
Disease control Recruiting nowThis study is testing whether adding immunotherapy drugs to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced colorectal cancer. Researchers want to see if the combination helps eliminate more cancer cells before surgery an…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Major cancer trial tests breakthrough drug combos for Tough-to-Treat esophageal tumors
Disease control Recruiting nowThis large study aims to find the best treatment combination for patients with esophageal or stomach junction cancer that cannot be surgically removed. Researchers will test whether adding newer immunotherapy drugs or targeted therapies to standard chemotherapy and radiation impr…
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New 'De-Chemo' combo aims to shrink tumors for better surgery in ovarian cancer
Disease control Recruiting nowThis study is testing a two-drug combination (fuzuloparib and apatinib) as a treatment given before surgery for advanced ovarian cancer. The goal is to see if this non-chemotherapy approach can shrink tumors enough to make complete surgical removal more likely, potentially improv…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for breast cancer patients in critical condition
Disease control Recruiting nowThis study is testing if a new drug called Trastuzumab Rezetecan (SHR-A1811) works better than standard chemotherapy for people with a severe form of advanced breast cancer. It is for patients whose cancer has spread and is causing rapid organ failure, a life-threatening situatio…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
First-in-China trial tests 'Living Drug' for Tough-to-Treat prostate cancer
Disease control Recruiting nowThis is an early-stage study testing a new type of cell therapy for men with advanced prostate cancer that has spread and no longer responds to standard hormone treatments. Researchers will give patients immune cells (NK cells) that have been specially engineered in a lab to targ…
Phase: EARLY_PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Looking back to see how a lung cancer treatment holds up over time
Disease control Recruiting nowThis study looks back at long-term survival data from a previous trial to see how well a specific immunotherapy drug works over time for patients with advanced squamous non-small cell lung cancer. It involves 109 patients who received the drug combined with chemotherapy as their …
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Custom cancer care: tailoring treatment to each Patient's response
Disease control Recruiting nowThis study is testing a personalized treatment approach for breast cancer that has spread to nearby lymph nodes. Researchers want to see if adjusting radiation, surgery, and drug therapy based on how well a patient's tumor responds to initial chemotherapy can help keep the cancer…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New drug combo aims to stop stomach Cancer's return
Disease control Recruiting nowThis study is testing whether adding an immunotherapy drug (sintilimab) to standard chemotherapy after surgery helps prevent stomach or esophageal junction cancer from coming back. It will involve about 70 adults with stage III cancer who have already had surgery to remove their …
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New combo therapy aims to shrink tumors before stomach cancer surgery
Disease control Recruiting nowThis study is testing a treatment plan that combines an immunotherapy drug (adebrelimab) with several chemotherapy drugs for people with a type of stomach or gastroesophageal cancer that can be removed with surgery. The goal is to see if giving this combination before and after s…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Smart radiation aims to zap cancer, spare patients
Disease control Recruiting nowThis study is testing a more precise form of radiation therapy called an 'adaptive boost' for prostate and bladder cancer. It aims to see if this approach can control the cancer while causing fewer side effects like urinary or bowel problems. The study will enroll 60 adults who a…
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
Mice help pick your chemo: new test aims to stop Cancer's return
Disease control Recruiting nowThis study is testing a personalized approach to prevent bile duct cancer from coming back after surgery. For each patient, tiny pieces of their tumor are tested in mice to see which chemotherapy drugs work best against it. The goal is to see if using this 'mini lab' test to choo…
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
First-of-its-Kind inhaled powder vaccine tested for Tough-to-Treat lung cancers
Disease control Recruiting nowThis is an early-stage study testing the safety of a new type of inhaled vaccine for people with advanced lung cancer or other cancers that have spread to the lungs. The vaccine is a dry powder containing mRNA designed to teach the immune system to attack cancer cells. The study …
Phase: EARLY_PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New combo therapy aims to stop aggressive liver Cancer's return
Disease control Recruiting nowThis study is for people who had surgery for liver cancer but are at high risk of it coming back. It compares two different follow-up treatments to see which is better at keeping the cancer away. One group gets a combination of targeted radiation and an immunotherapy drug. The ot…
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New Two-Pronged drug joins fight against advanced cervical cancer
Disease control Recruiting nowThis study is testing whether adding a new immunotherapy drug called QL1706 to the standard treatment of chemotherapy and radiation works better for women with locally advanced cervical cancer. The drug aims to help the body's immune system fight the cancer. Researchers will enro…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Personalized vaccine trial offers new hope for lung cancer patients who stopped responding to treatment
Disease control Recruiting nowThis study is testing a new personalized cancer vaccine called LK101, given alongside existing immunotherapy drugs, for people with advanced lung cancer. It is specifically for patients whose cancer has continued to grow despite previous immunotherapy treatment. The main goals ar…
Phase: PHASE1, PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New drug combo tested to keep aggressive lung cancer at bay
Disease control Recruiting nowThis study is testing whether adding a new drug called golidocitinib to standard immunotherapy (PD-1 inhibitors) can help control extensive-stage small cell lung cancer for longer. After initial chemotherapy, participants receive the two-drug combination as maintenance therapy to…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New drug trial aims to stop early lung cancer from returning
Disease control Recruiting nowThis study is testing whether a drug called tislelizumab can help prevent early-stage lung cancer from coming back after surgery. It will involve about 108 adults who have had surgery to remove their cancer but are at higher risk of it returning. The main goal is to see if the dr…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New hope for liver cancer patients as experimental drug enters first human trials
Disease control Recruiting nowThis is a very early-stage study to test the safety of a new drug called CREPT-618 in adults with advanced liver cancer that has stopped responding to standard treatments. The main goal is to find a safe dose by giving small groups of patients increasing amounts of the drug and w…
Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
Scientists test cord blood injection to boost platelets in cancer patients
Disease control Recruiting nowThis is an early-stage study to see if a new cell therapy called XJ-MK-002 is safe and can help raise platelet counts. The therapy involves a single injection of cells derived from umbilical cord blood. Researchers will test three different doses in a small group of adult cancer …
Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
High-Tech radiation zaps prostate cancer with pinpoint accuracy
Disease control Recruiting nowThis study is testing a new, highly precise form of radiation therapy for men with prostate cancer that has not spread widely. It uses a special machine that combines an MRI scanner with a radiation beam to target tumors more accurately while trying to spare healthy tissue. The m…
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Doctors test powerful, quick radiation blast to shrink tough abdominal tumors before surgery
Disease control Recruiting nowThis study is testing a new approach for a rare abdominal cancer called retroperitoneal sarcoma. Doctors want to see if giving a few very high doses of targeted radiation before surgery is safe and helps control the tumor. The study will enroll 50 patients to check for complicati…
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New immune cell attack tested for tough prostate cancer
Disease control Recruiting nowThis early-stage study is testing a new type of immunotherapy for men with advanced prostate cancer that has stopped responding to standard hormone treatments. Doctors are using specially engineered immune cells, called CAR-NK cells, designed to find and kill prostate cancer cell…
Phase: EARLY_PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New immune cell therapy targets advanced ovarian Cancer's painful fluid buildup
Disease control Recruiting nowThis study is testing a new immune cell therapy for women with advanced ovarian cancer who have severe fluid buildup in the abdomen and have run out of standard treatment options. Doctors will infuse specially activated immune cells directly into the abdominal cavity once a week …
Phase: PHASE1, PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New combo attack on sarcoma before surgery
Disease control Recruiting nowThis study is testing a two-part treatment for soft tissue sarcoma in the arms, legs, or trunk before surgery. It combines a targeted form of radiation with a drug called anlotinib, aiming to shrink the tumor and make surgery more effective. The main goal is to see if this approa…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New hope for rare blood disorder: testing a gentler chemo combo
Disease control Recruiting nowThis study is testing whether a combination of two existing drugs—a low-dose chemotherapy (cytarabine) and thalidomide—can effectively control Langerhans cell histiocytosis (LCH) in adults who haven't had treatment before. It aims to see if this regimen can keep the disease in ch…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
Four-Drug attack on advanced head & neck cancer begins human testing
Disease control Recruiting nowThis study is testing a new combination of four drugs as the first treatment for people whose nasopharyngeal cancer (a type of head and neck cancer) has returned or spread. The goal is to see if adding two targeted drugs (nimotuzumab and toripalimab) to standard chemotherapy (gem…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 17, 2026 13:08 UTC
-
New combo therapy aims to shrink tumors before liver cancer surgery
Disease control Recruiting nowThis study is testing a three-part treatment given before surgery for patients with liver cancer that has a high chance of coming back. Doctors combine a procedure that delivers chemotherapy directly to the tumor (TACE) with two immunotherapy drugs (atezolizumab and bevacizumab).…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 17, 2026 13:08 UTC
-
Simple urine test could personalize cancer treatment
Diagnosis Recruiting nowThis study aims to see if proteins in urine can predict how well patients with locally advanced colorectal cancer will respond to pre-surgery (neoadjuvant) therapy. Researchers will collect urine samples from 400 patients before and after treatment, using advanced protein analysi…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Diagnosis
Last updated Mar 02, 2026 15:21 UTC
-
Doctors track 500 patients to find best surgery after cancer treatment
Knowledge-focused Recruiting nowThis study follows 500 lung cancer patients who receive immunotherapy drugs before surgery. Researchers want to learn which surgical approach works better after this treatment and whether surgery provides more benefit than radiation. The study tracks patients' long-term health an…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC